ICCON
CRL icon

Investment Counsel Company of Nevada’s Charles River Laboratories CRL Stock Holding History

Investment Counsel Company of Nevada’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1
Closed -$185 – 75
2024
Q4 		$185 Buy
+1
New +$193 ﹤0.01% 94

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Investment Counsel Company of Nevada's CRL Position: Q1 2025 in Review

Investment Counsel Company of Nevada sold out of Charles River Laboratories (CRL) in Q1 2025, closing a stake of 1 share — an estimated $185 sold.

Investment Counsel Company of Nevada first reported a position in CRL in Q4 2024 and held it in 1 quarter. The position peaked at $185 in Q4 2024. 561 funds tracked by Wall St. Rank hold CRL as of Q1 2025.

  • Investment Counsel Company of Nevada reported no remaining Charles River Laboratories position as of Q1 2025 after selling out during the quarter.
  • Investment Counsel Company of Nevada sold 1 Charles River Laboratories share in Q1 2025, an estimated $185.
  • Investment Counsel Company of Nevada first reported a position in Charles River Laboratories in Q4 2024 and held it in 1 quarter.
  • Investment Counsel Company of Nevada's Charles River Laboratories position peaked at $185 in Q4 2024.
  • 561 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.

Based on Investment Counsel Company of Nevada's 13F filing for Q1 2025, filed 9 May 2025.